Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RXII

RXi Pharmaceuticals (RXII) Stock Price, News & Analysis

RXi Pharmaceuticals logo

About RXi Pharmaceuticals Stock (NASDAQ:RXII)

Advanced Chart

Key Stats

Today's Range
$2.33
$2.49
50-Day Range
$0.36
$0.50
52-Week Range
$0.31
$7.70
Volume
84,045 shs
Average Volume
1.73 million shs
Market Capitalization
$10.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive RXII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RXi Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RXII Stock News Headlines

Rex International Holding Ltd (RXI.SG)
Galena's Breast Cancer Vaccine Doomed to Fail
Something very strange is happening...
What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone noticed when the U.S. Senate granted sweeping powers to a Harvard economist who has some dangerous ideas about the U.S. dollar. Now, he's issued a blueprint for what a coming "Mar-a-Lago Accord" could look like. One analyst who predicted the 2008 crisis says this plan could see the dollar fall in value by 40% in months and become a national nightmare.
Q4 2022 Catalyst Pharmaceuticals Inc Earnings Call
iShares Global Consumer Discretionary ETF (RXI)
See More Headlines

RXII Stock Analysis - Frequently Asked Questions

RXi Pharmaceuticals Co. (NASDAQ:RXII) posted its quarterly earnings data on Tuesday, August, 14th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.16. The biotechnology company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.02 million. RXi Pharmaceuticals had a negative trailing twelve-month return on equity of 412.15% and a negative net margin of 4,990.20%.

RXi Pharmaceuticals's stock reverse split before market open on Monday, January 8th 2018.The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that RXi Pharmaceuticals investors own include Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Endologix (ELGX), Auris Medical (EARS), Protalix BioTherapeutics (PLX) and Anavex Life Sciences (AVXL).

Company Calendar

Last Earnings
8/14/2018
Today
7/04/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RXII
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.45 million
Net Margins
-4,990.20%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10 thousand
Price / Cash Flow
N/A
Book Value
$0.77 per share
Price / Book
3.12

Miscellaneous

Free Float
N/A
Market Cap
$10.51 million
Optionable
Not Optionable
Beta
2.07
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:RXII) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners